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Introduction
Acinetobacter baumannii is a nonmotile, Gram-negative, 
nonfermentative, oxidase-negative, and aerobic Bacilli, 
which is one of the most opportunistic pathogens against 
human.[1,2] The bacteria are widespread in the environment 
and are considerably resistant to most antibiotics, low 
nutrient, and arid condition.[3] Acinetobacter spp. cause a 
variety of nosocomial infections, but A. baumannii is the 
prevalent species with high morbidity and mortality, including 
pneumonia, bacteremia, urinary tract, and skin and soft tissue 
infections, especially in patients with severe illness.[1,3,4] At 
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Abstract
Background: Metallo‑beta‑lactamase (MβL) enzymes production is one of the most important 
resistance mechanisms against carbapenems in some bacteria including Acinetobacter baumannii. 
Aims: This study was aimed to determine the antimicrobial susceptibility and the prevalence 
of MβL among carbapenem‑resistant isolates of A. baumannii. Materials and Methods: In 
this cross‑sectional study from October 2012 to April 2013, 98 isolates were identified as 
A. baumannii using Microgen™ kits and confirmed by molecular method. These isolates were 
tested for antimicrobial susceptibilities by disk diffusion method according to the Clinical and 
Laboratory Standards Institute guidelines. Carbapenem‑resistant isolates were further detected 
phenotypically by MβL minimal inhibitory concentration (MIC)‑test strips, and subsequently 
positive MβL isolates were confirmed by polymerase chain reaction (PCR). Results: Overall, 
98% (96/98) of A. baumannii isolates were detected as carbapenem‑resistant by MIC test. 
Highest sensitivity to the tested antibiotic with 42.9% (42/98) was observed to colistin. Of 96 
carbapenem‑resistant isolates, 43 were phenotypically positive for MβL; out of 43 isolates, 37 
were confirmed for the presence of MβL genes by PCR. Conclusion: The frequency of drug 
resistance among the clinical samples of A. baumannii isolated in our study against most of 
the antibiotics was very high. Moreover, all MβL producing isolates were multidrug resistance. 
Therefore, systematic surveillance to detect MβL producing bacteria and rational prescription 
and use of carbapenems could be helpful to prevent the spread of carbapenem resistance.
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of nosocomial infections by multidrug-resistant (MDR) A. 
baumannii in the Intensive Care Units (ICUs) have led to rise 
mortalities at the hospitals.[5-7]
A. baumannii has propensity to acquire resistance; a mechanism 
of this resistance is being characterized by the production of 
a specific enzyme called metallo‑beta‑lactamases (MβLs).[4,7] 
These enzymes belong to Ambler class B beta-lactamases 
based on their amino acid sequence homology and to Group 3 
according to the Bush classification based on their substrate 
profiles (imipenem hydrolysis).[7] These enzymes are inhibited 
by ethylenediaminetetraacetic acid (EDTA).[8]
In Iran, several studies have previously been carried out on 
drug resistance of A. baumannii, revealing a high resistance 
rate to most of the antibiotics.[9-11] However, a few studies have 
been conducted in Iran, especially in our region, aiming to 
find the prevalence of MβL producing genes among clinical 
isolates of A. baumannii. The aims of the present study were to 
investigate MDR and determine the prevalence of MβL genes 
among carbapenem-resistant isolates of A. baumannii from 
clinical specimens in Shiraz, Southwest of Iran.
Materials and Methods
Sampling and bacterial isolates
In this cross-sectional study from October 2012 to April 
2013, 120 Acinetobacter isolates were recovered from clinical 
specimens. The specimens were randomly collected from 
patients in different wards of two hospitals, Nemazee and 
Faghihi in Shiraz, a major city in Southwest of Iran. Nemazee 
and Faghihi hospitals are the two major tertiary care hospitals 
with 1000 beds, affiliated to Shiraz University of Medical 
Science, Shiraz, Iran. Sample size was calculated as about 
100 using the formula[12]:
2á1
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The study was in accordance with declaration of Helsinki; 
however, because we only used laboratory clinical specimens 
and did not harm any of the patients, the local ethics committee 
waived the need for informed consent.
Totally, 98 isolates were identified as A. baumannii isolates 
using Microgen™ diagnosis Kits. These 98 isolates were 
recovered from 35 sputum, 15 wound swab, 13 body fluids, 
9 blood, 9 urine, 8 endotracheal tube, 5 cerebrospinal fluid, 
and 4 other samples (included 2 bronchoalveolar lavage, 1 eye 
swab, and 1 axillary swab). Overall, 53 samples were collected 
from ICUs and 45 samples from other wards (included 
gastroenterology, skin, surgery, and transplant) in the two 
above‑mentioned hospitals. Confirmed isolates were kept 
at − 70°C until for long preservation.
Antimicrobial susceptibility testing
The susceptibility of the isolates to 16 antibiotics disk (MAST, 
UK) was investigated using disk diffusion method according 
to the Clinical and Laboratory Standards Institute (CLSI) 
recommendation.[13] The test was performed on Mueller-Hinton 
agar (Merck, Germany) with followed antibiotics disks 
containing 10 μg imipenem, 10 μg meropenem, 30 μg amikacin, 
10 μg gentamicin, 30 μg aztreonam, 30 μg ceftazidime, 5 μg 
ciprofloxacin, 5 μg levofloxacin, 100 μg piperacillin, 10 μg 
tobramycin, 25 μg colistin, 20 μg ampicillin/sulbactam, 10 μg 
ampicillin, and 110 μg piperacillin/tazobactam. Pseudomonas 
aeruginosa ATCC 27853 was used as the control strain in 
susceptibility testing.
Minimal inhibitory concentration
Minimal inhibitory concentration (MIC)‑test strips (Liofilchem, 
Italy), containing imipenem and meropenem, were used to 
determine the MIC according to the instruction provided by the 
company on Muller-Hinton agar (Merck, Germany). Results 
were interpreted using CLSI criteria.
Phenotypic metallo‑beta‑lactamase detection
MIC-test strip (Liofilchem, Italy), containing imipenem/
imipenem + EDTA, was used to determine the phenotypic 
MβL enzyme production. MIC-test strip was performed 
according to the manufacturer’s instructions. A reduction in 
the MIC of imipenem of ≥ 3 dilutions in the presence of EDTA 
was interpreted as a positive test. In addition, a strain was 
considered MβL producer if a phantom zone or deformation 
of the eclipse was observed.
DNA extraction and molecular typing
The isolates which were intermediately resistant or 
resistant to imipenem or meropenem were considered 
carbapenem-resistant. Extraction of genomic DNA from A. 
baumannii isolates was performed according to the protocol 
as previously described.[14] Polymerase chain reaction (PCR) 
assay was performed for the detection of blaOXA-51-like gene, 
a 353 base-pair (bp) amplicon, as an internal gene for 
molecular confirmation of A. baumannii isolates at the 
species level (primer sequence: F/5’‑TAA TGC TTT GAT 
CGG CCT TG‑3′, R/5′‑TGG ATT GCA CTT CAT CTT 
GG‑3′),[15] and for amplification of MβL encoding genes, 
blaIMP, blaVIM, and blaSPM using the following consensus 
primer sets, blaIMP: F/5’‑GAA GGC GTT TAT GTT CAT 
AC‑3’, blaIMP: R/5’‑GTA TGT TTC AAG AGT GAT GC‑3’ 
which amplify a 587 bp amplicon, blaVIM: F/5’‑GTT TGG 
TCG CAT ATC GCA AC‑3’, blaVIM: R/5’‑AAT GCG CAG 
CAC CAG GAT AG‑3’ which amplify a 382 bp amplicon,[16] 
and blaSPM: F/5’‑AAA ATC TGG GTA CGC AAA CG‑3’, 
blaSPM: R/5’‑ACA TTA TCC GCT GGA ACA GG‑3’ which 
amplify a 271 bp amplicon.[17] A P. aeruginosa harboring 
blaIMP, blaVIM, blaSPM genes (obtained from Pasteur Institute 
of Iran) was used as the positive control.[18]
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Statistical analysis was performed using SPSS™ software 
version 19.0 (IBM Corp., Armonk, NY, USA). The results for 
infectious agents and antimicrobial susceptibility presented as 
descriptive statistics in terms of relative frequency. Chi-square 
or Fisher’s exact test was used to analyze the results wherever 
they needed. P < 0.05 was considered as statistically significant 
clinical relevance.
Results
Of 98 A. baumannii isolates, 54.1% (53/98) of isolates were 
collected from female patients’ samples. Seventy isolates 
were obtained from Namazee and 28 from Faghihi Hospital. 
Most of the 98 A. baumannii isolates were recovered from 
sputum (n = 35), wound swab (n = 15), and body fluids (n = 13).
The highest antibiotic resistance rates were observed against 
aztreonam, ceftazidime, ciprofloxacin, piperacillin, and 
cefotaxime since all of the tested isolates showed resistance. 
In addition, no sensitive isolates were seen against aztreonam 
and cefotaxime; just a few isolates were in the intermediate 
level of susceptibility. The results of antibiotic susceptibility 
patterns for the tested isolates are displayed [Table 1].
Totally, 98% (96/98) of the isolates were detected as 
carbapenem-resistant by MIC-test strip. Among the 
carbapenem-resistant A. baumannii isolates, 44.8% (43/96) 
were found to be MβL producers by MβL MIC-test strips. 
Interestingly, the majority 85.7% (84/98) of the isolates showed 
an MIC ≥ 48 μg/ml. MIC ranges for the tested isolates to 
imipenem are presented in Table 2. All phenotypically MβL 
producing isolates were MDR and exhibited high resistance 
to beta-lactams, aminoglycosides, and fluoroquinolones. 
Furthermore, three of the MβL producing isolates were 
sensitive to ampicillin-sulbactam.
Finally from MβL producing isolates, 86% (37/43) were 
positive for MβL genotypes, of which 53.4% (23/43) isolates 
carried blaIMP, 32.6% (14/43) carried blaVIM MβL genes, and 
none of the isolates carried blaSPM gene. PCR results for 
amplification of MβL producing genes are displayed in Table 3.
From the total ICUs recovered isolates, 47.2% (25/53) carried 
one of the blaIMP or blaVIM genes; this rate for isolates from 
other hospital wards was 26.7% (12/45). Despite the higher 
proportion for blaIMP and blaVIM gene in ICUs compared to other 
wards, no significant differences were observed (P = 0.06). The 
frequencies of blaIMP and blaVIM genes for Namazee hospital 
isolates were 22.9% (16/70)  and 12.9% (9/70), respectively. 
The similar rates for Faghihi Hospital isolates were 25% (7/28) 
for blaIMP and 17.9% (5/28) for blaVIM genes.
Discussion
One of the carbapenem resistance mechanisms is production 
of carbapenem-hydrolyzing β-lactamases, which is called 
carbapenemase; one of them, MβL is more important in drug 
resistance against carbapenems.[7,19]
In the recent years, there have been numerous reports on MDR 
A. baumannii from hospital settings in Iran.[10-11] In most of 
these studies, only characterized isolates were obtained from 
ICUs while this study attempted to determine the resistance 
among isolates obtained from various medical wards as well. In 
particular, 45 clinical samples were isolated from wards outside 
ICUs. Antibiotic susceptibility testing showed that the majority 
of the isolates were resistant to three or more antibiotics [Table 1] 
while all the isolates were resistant to imipenem, cefotaxime, and 
ciprofloxacin, and 95% and 96% of the isolates were resistant 
to meropenem and amikacin, respectively.
Carbapenems are the best choice for nosocomial infections of 
Acinetobacter in Iran. However, in the recent years, it has been 
reported that there is reduced susceptibility to imipenem.[10,11,20] 
Table 1: Susceptibility patterns of Acinetobacter baumannii 
isolates to 16 tested antibiotics by disc diffusion method
Antibiotic disks Total (n=98) n (%)
Sensitive Intermediate Resistance
Meropenem 3 (3.1) 0 95 (96.9)
Imipenema 4 (4.1) 0 94 (95.9)
Amikacin 24 (24.5) 6 (6.1) 68 (69.4)
Gentamicin 13 (13.3) 11 (11.2) 74 (75.5)
Aztreonam 0 0 98 (100)
Cefoxitin 0 0 98 (100)
Ceftazidime 0 0 98 (100)
Ciprofloxacin 0 0 98 (100)
Levofloxacin 0 0 98 (100)
Piperacillin 0 0 98 (100)
Piperacillin‑tazobactam 0 0 98 (100)
Ampicillin 0 0 98 (100)
Ampicillin‑sulbactam 5 (5.1) 0 93 (94.9)
Colistin 42 (42.9) 0 56 (57.1)
aResistance rate against imipenem using MIC was 99%, which is higher compared to 96% 
detected by disc diffusion method. MIC: Minimal inhibitory concentration
Table 2: Distribution of resistance rate of the studied 
Acinetobacter baumannii isolates to imipenem by E‑test 






2 24 32 48 64 98 128 Total 
number
Sputum 0 1 2 2 10 9 11 35
Wound 1 0 0 2 3 4 5 15
Body fluids 0 1 0 2 1 7 2 13
Urine 0 1 2 1 2 3 0 9
Blood 0 0 1 2 2 4 0 9
ETTa 0 2 1 2 2 1 0 8
CSFb 1 0 1 2 0 1 0 5
Other 0 0 0 2 1 0 1 4
Total number 2 5 7 15 21 29 19 98
aETT: Endotracheal tube, bCSF: Cerebrospinal fluid. MIC: Minimal inhibitory concentration
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Further, resistance to colistin, polymyxin, and tigecycline 
which are the usual choices for nosocomial infections of 
carbapenem‑resistance Acinetobacter is increased around the 
world, especially in Iran.[10,11,21] Our results suggest colistin 
as the best choice for A. baumannii isolates in‑vitro; this is in 
accordance with the finding of Japoni‑Nejad et al. from Arak, 
Central area of Iran, that reported colistin and tigecycline as the 
most effective antibiotic agents against A. baumannii isolates.[10]
In a relatively similar study, Feizabadi et al. reported the 
prevalence of susceptibility of A. baumannii to imipenem, 
meropenem, piperacillin-tazobactam, and amikacin rate of 
50.7%, 50%, 42.1%, and 38.2%, respectively.[22] These rates 
indicated higher sensitive isolates compared to our rates with 
4.1%, 3.1%, 0%, and 24.5%, respectively. Our results showed 
a higher resistance rate of A. baumannii isolates against most of 
the studied antibiotics which were almost similar compared to 
some studies carried out throughout Iran and other countries.[23-25]
In this study, of the 96 (98%) carbapenem-resistant A. 
baumannii, 44.8% were found to be MβL producers by 
MIC-test strips. Such a high resistance rate to imipenem is 
not uncommon since two separate studies by Safari et al.  and 
Noori et al. have previously shown 99% resistance among 
their tested isolated by MIC-test strips and disk diffusion 
methods, respectively.[11,21] Abdalhamid et al. from Saudi 
Arabia, in contrast with Iranian studies, reported lower 
carbapenem-resistant A. baumannii (46/141; 32.6%); 
however, MβL was much higher than that of Iranian report 
since 43 of 46 carbapenem-resistant A. baumannii isolates 
were MβL positive.[26]
All MβL producing isolates in our study were MDR and 
exhibited high resistance to beta-lactams, aminoglycosides, 
and fluoroquinolones. This high rate of MDR in our study 
was in agreement with a study from our neighboring country, 
Pakistan, which reported the prevalence of MDR 100% among 
A. baumannii isolates.[27] Three of our MβL-producing isolates 
were sensitive to ampicillin-sulbactam.
In the present study, from a total of 43 MβL producing isolates, 
86% were positive for MβL genotypes and subsequently 53.4% 
and 32.6% of the isolates carried blaIMP and blaVIM genes, 
respectively.
As it is seen in our results, phenotypic and genotypic results 
of the detection of MβL producing isolates were not the same. 
Possible reason of higher positive rates for phenotypic MβL 
production could be the presence of MβL genes other than 
those we have screened.[28,29]
In a previous Iranian study conducted in Tabriz, from a total of 
63 carbapenem-resistant A. baumannii, 31 (49%) were found 
to be MβL producers by MIC-test strips, of which 19 isolates 
carried blaIMP and 9 carried blaVIM genes; these rates were 
remarkably close to our findings.[20] In addition, Noori et al. 
from the capital of Iran reported a blaIMP-1 gene prevalence of 
3 of 86 (3.48%) among MβL A. baumannii isolates.[21]
In the current study, no blaSPM gene was detected among 
A. baumannii isolates; previously, two similar attempts for 
detection of blaSPM gene by Shahcheraghi et al. (2009–2010) 
and Noori et al. (2012–2013) were made in Tehran, Iran; only, 
Shahcheraghi et al. was able to detect this gene in 6 out of 100 
tested A. baumannii isolates.[18,21] Reports about the prevalence 
of these genes among A. baumannii isolates from other parts 
of the world have shown different patterns. Abdalhamid et al. 
from Saudi Arabia and Al-Agamy et al. from Egypt reported 
negative PCR results for blaIMP, blaVIM, and blaSPM genes 
among all MβL producing isolates.[26,30] However, previously, 
blaIMP and blaVIM prevalences have been reported from Greece, 
China, Korea, and India.[31-34] The present study has some 
limitations. First, lack of DNA sequencing for knowing the 
IMP and VIM variants must be mentioned as a limitation of 
our study. Moreover, employed a typing method could clear 
the connection between isolates and source of infections in 
studied hospitals.
Conclusion
The prevalence of drug resistance among the clinical 
samples of A. baumannii isolated in our study against most 
of the antibiotics is very high. Hence, early detection and 
optimization of infection control practices are the best defenses 
Table 3: Distribution of metallo‑beta‑lactamase genes 
among the studied Acinetobacter baumannii isolates
MβL gene Sample Place of isolation Total number
IMP‑1 Sputum ICU 6
IMP‑1 Sputum Gastroenterology 2
IMP‑1 Body fluids ICU 2
IMP‑1 Wound ICU 2
IMP‑1 Wound NICU 1
IMP‑1 Wound Transplant 1
IMP‑1 Blood ICU 2
IMP‑1 Blood Transplant 1
IMP‑1 ETTa NICU 2
IMP‑1 ETT ICU 1
IMP‑1 Urine ICU 2
IMP‑1 CSFb ICU 1
VIM‑2 Sputum ICU 2
VIM‑2 Sputum Gastroenterology 1
VIM‑2 Wound ICU 2
VIM‑2 Wound NICU 1
VIM‑2 Urine ICU 2
VIM‑2 Blood ICU 1
VIM‑2 Blood NICU 1
VIM‑2 Body fluids ICU 1
VIM‑2 CSF ICU 1
VIM‑2 ETT Gastroenterology 1
VIM‑2 Other NICU 1
aETT: Endotracheal tube, bCSF: Cerebrospinal fluid. MβL: Metallo‑beta‑lactamase, 
ICU: Intensive Care Unit, NICU: Neonatal Intensive Care Unit
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against these organisms. Therefore, systematic surveillance to 
detect MβL producing bacteria and rational prescription and 
use of carbapenems could be helpful to prevent the spread of 
carbapenem resistance.
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